Solentim are pleased to announce the appointment of Dr Julian Burke as a non-executive Director. A former lecturer in Biochemistry at the University of Sussex, UK, Dr Burke has over 25 years’ experience of executive leadership positions in life science companies. He was Chief Scientific Officer for Genetix Group PLC from 2000 – 2010 until …
As part of the concerted fight against COVID-19, the Vaccine Research Center (VRC) at the National Institute for Allergy and Infectious Diseases at the U.S. National Institutes of Health has invested in two key technology platforms from Solentim: the VIPS™ (Verified In-Situ Plate Seeding) high efficiency single cell seeder, and the Cell Metric® high contrast …
Bournemouth, UK, 7th October 2020 / Solentim is pleased to announce the adoption of its VIPS™ single cell seeding platform and Cell Metric® CLD into Samsung Biologics’ new research and development facility in San Francisco, CA. These instruments are designed for single cell cloning and assurance of monoclonality to increase the speed and efficiency of Master Cell Bank development. Samsung’s new R&D …
VIPS™ + MatriClone™ combination ensures high efficiency seeding of hiPSCs with high viability Solentim, the global leader for solutions to create, isolate and characterize the highest value cells for the development of new biological medicines, yesterday launched a dedicated new workflow for single cell cloning of human induced pluripotent stem cells (hiPSCs). A combination of Solentim’s VIPS™ (verified in-situ plate seeding) instrument …
Read more Solentim launches new workflow for single cell cloning of stem cells
The Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland has adopted the market-leading Cell Metric® whole well imaging system from Solentim to support its Rapid Response Vaccine Pipeline. The UQ team was funded by Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership launched in 2017 to develop vaccines to stop …
Solentim, the world leader in instruments and workflow solutions to create, isolate and characterize the highest value cells for the development of new biological medicines and therapies reports another record year for the 12 months to June 2020. Solentim has achieved record revenue growth from instrument sales and service support, with particular strength in the …
Read more Continued growth and progress for Solentim: 2019/2020 highlights
